PROGRAMME Poster Presentations
Poster Session 01 - Helicobacter 1
P01.01.
Microbiome-targeted nutritional support as an independent predictor of successful Helicobacter pylori eradication: a prospective controlled study
Iryna Paliy, Vinnytsya, Ukraine
P01.02.
Entosis-Associated Giant Macroautophagy in Parietal Cells: A Novel Marker of Non–Helicobacter pylori Helicobacter Infection
Masahiko Nakamura, Isehara, Japan
P01.03.
Efficacy and safety of fexuprazan-based modified high-dose dual therapy for Helicobacter pylori eradication
JIYONG AHN, Seoul, Korea, Republic of
P01.04.
First-line empirical eradication therapy for Helicobacter pylori infection: Experience from 1,500 cases of the Brazilian Registry on H. pylori management (Hp-BrazilReg/WorldHpReg)
Luiz G. V. Coelho, Belo Horizonte, Brazil
P01.05.
Helicobacter pylori empirical first-line and rescue treatments in patients allergic to penicillin: experience among 2,700 cases of the European Registry on H. pylori Management (Hp-EuReg)
Olga P. Nyssen, Madrid, Spain
P01.06.
Real-world effectiveness of first-line-treatment for H. pylori infection in a high-resistance setting: A 2-year single-center study
I. Sasiakos, Athens, Greece
P01.07.
Challenges in Helicobacter pylori Detection and Gastroduodenal Symptoms in Patients with Rheumatologic Diseases
Gulustan Babayeva, Baku, Azerbaijan
P01.08.
Efficacy and safety of 7-day vonoprazan-amoxicillin-minocycline triple therapy for Helicobacter pylori eradication: a pilot study
Jiarui Zhou, Chengdu, China
P01.09.
Protective efficacy of a multi-strain synbiotic against antibiotic-associated gastrointestinal disorders during Helicobacter pylori eradication
Iryna Paliy, Vinnytsya, Ukraine
P01.10.
Chitosan microparticle–delivered Mycobacterum bovis BCG modulates gastrointestinal immunity and reduces H. pylori colonization in a guinea pig model
Weronika Gonciarz, Lodz, Poland
P01.11.
Terpene-Based Eutectic Solvent Microdroplets: A Strategy to Combat Antibiotic-Resistant Helicobacter pylori
Weronika Gonciarz, Lodz, Poland
Poster Session 02 - Helicobacter 2
P02.01.
Regression of a Large Gastric Schwannoma with ulcer after Helicobacter pylori Eradication: A Case Report
Hirofumi Fukushima, Tokyo, Japan
P02.02.
Outcomes of first-line empirical Helicobacter pylori eradication therapy in Austria: data from the European Registry on the Management of H. pylori Infection (Hp-EuReg)
Andreas Blesl, Graz, Austria
P02.03.
Economic Evaluation of Tailored versus Empirical H. pylori Eradication across Varying Clarithromycin Resistance Levels
Joons Sung Kim, Seoul, Korea, Republic of
P02.04.
Reasons for the failure of eradication therapy. A clinical perspective.
Tatsiana Haurylenka, Gomel, Belarus
P02.05.
Sterol-grafted chitosan nanoparticles for targeted Helicobacter pylori eradication
Bruna Costa, Porto, Portugal
P02.06.
Primary Healthcare Patients' Awareness about Helicobacter Pylori Infection
Paulius Jonaitis, Kaunas, Lithuania
P02.07.
Pylori Rx - a mobile phone application for the management of Helicobacter pylori infection in Ireland.
Sinead Smith, Dublin, Ireland
P02.08.
Mechanisms of tetracycline resistance in Helicobacter pylori isolated from Korean patients
Jae Gyu Kim, Seoul, Korea, Republic of
P02.09.
Evaluation of a multi-target qPCR approach to detect Helicobacter pylori in oral rinse samples compared to the urea breath test
Marta Dobrić, Dublin, Ireland
P02.10.
Preclinical Safety Evaluation of a Novel Therapeutic Vaccine Against Helicobacter pylori: Repeated-Dose Toxicity, Local Tolerance, and Immunogenicity in Rats
Hassan Moeini, Munich, Germany
P02.11.
Investigating the Relationship Between Helicobacter pylori Infection and theDevelopment of Chronic Urticaria: A Serological Study in Dermatology Hospital BirAlOsta Milad, Libya
Maryam Omar, Tripoli, Libya
Poster Session 03 - Helicobacter 3
P03.01.
Tailored Therapy for H. pylori Based on Macrolide Exposure versus PCR Test: An Interim Analysis
Kee Don Choi, Ulsan, Korea, Republic of
P03.02.
Shaping Europe’s First Evidence-Based Guidelines for Gastric Cancer Prevention: The European Commission Initiative on Gastric Cancer
Jin Young Park, Lyon, France
P03.03.
Patients' Knowledge about Helicobacter Pylori Transmission, Clinical Significance and Treatment
Paulius Jonaitis, Kaunas, Lithuania
P03.04.
Optimization of Minocycline-Containing Bismuth Quadruple Therapy for Helicobacter pylori Rescue Treatment: A Randomized Controlled Trial
Hong Lu, Shanghai, China
P03.05.
Eradication therapy taking into account molecular genetic markers of H. pylori resistance to clerithromycin
Vera Poliakova, Moscow, Russian Federation
P03.06.
Real-world effectiveness of first-line Helicobacter pylori therapies in Germany: eradication outcomes in a low clarithromycin-resistance setting using data from the European Registry on H. pylori Management (Hp-EuReg)
Alexander Link, Erlangen-Nürnberg, Germany
P03.07.
Directed evolution of tetracycline, metronidazole and levofloxacin antibiotic resistance in Helicobacter pylori
Farah Mahmood, Nottingham, United Kingdom
P03.08.
Genetic progression of gastric cancers after helicobacter pylori infection
Sung Soo Kim, Uijeongbu, Korea, Republic of
P03.09.
Monitoring Helicobacter pylori prevalence and antimicrobial resistance in Ghent, Belgium.
Anne-Marie Van den Abeele, Ghent, Belgium
P03.10.
Helicobacter pylori stool antigen testing revisited.
Anne-Marie Van den Abeele, Ghent, Belgium
P03.11.
Effectiveness of first-line Helicobacter pylori treatment in Europe: real-world evidence from a 13-year analysis of 68,361 patients from the European Registry on H. pylori Management (Hp-EuReg)
Samuel J. Martínez-Domínguez, Zaragoza, Spain
Poster Session 04 - Helicobacter 4
P04.01.
Relevance of Sex on Helicobacter pylori Eradication Therapy: Experience from the European Registry on H. pylori Management (Hp-EuReg)
Diego Casas Deza, Zaragoza, Spain
P04.02.
Impact of Helicobacter pylori treatment during dual antiplatelet therapy on the prevention of gastrointestinal bleeding
Beom Jin Kim, Seoul, Korea, Republic of
P04.03.
Influence of ethnicity on Helicobacter pylori eradication therapy: results from the European Registry on H. pyloriManagement (Hp-EuReg)
Olga P. Nyssen, Madrid, Spain
P04.05.
Temporal patterns and inter-centre variability in first-line empirical eradication therapy for Helicobacter pylori infection in Europe: analysis of the European Registry on H. pylori Management (Hp-EuReg)
Angeles Perez Aisa, Marbella, Spain
P04.06.
Clinical and metrological validation of a portablemass spectrometer for decentralised Helicobacterpylori breath testing
Giulia Fiorini, Bologna, Italy
P04.07.
Empirical second-line therapy for Helicobacter pylori infection in Italy: data from the Italian Registry on Helicobacter pylori treatment (Hp-ItaReg)
Rocco Maurizio Zagari, Bologna, Italy
P04.08.
The impact of subinhibitory levels of antibiotics on Helicobacter pylori biofilm rheology
Paweł Krzyżek, Wroclaw, Poland
P04.09.
The efficacy of Standard Triple Therapy for Treatment of Helicobacter pylori Infection in Dyspeptic Children and Adults in Tripoli, Libya
Abdurrazag Nami, Kasr Khiar, Libya
P04.10.
The relationship between the detection of antibodies to the CagA virulence factor and serological markers of gastric mucosal atrophy among H.pylori – infected in the Moscow population
Dmitry Bordin, Moscow, Russian Federation
P04.11.
Effectiveness of empirical first-line eradication therapy for Helicobacter pylori infection according to age: data from the Latin American Registry on the Management of H. pylori Infection (Hp-LATAMReg).
Arnoldo Riquelme, Santiago, Chile
Poster Session 05 - Microbiota 1
P05.01.
From laboratory to real clinical practice: a multidisciplinary approach towards the next probiotics
Matteo Pavoni, Bologna, Italy
P05.02.
Coexistence of right-sided ulcerative colitis and suspected eosinophilic esophagitis with complex gastroduodenal motility disorders: a case report
Pavels Janovics, Riga, Latvia
P05.03.
Neisseria perflava, an oral microbiome species isolated from the gastric mucus of gastric cancer surgery patients, induces interleukin-8 production in gastric epithelial cells via a NOD1-dependent mechanism
Jae Gyu Kim, Seoul, Korea, Republic of
P05.04.
Respiratory and intestinal microbiota shifts in asthma with coexisting depression
Konrad Lehr, Erlangen-Nürnberg, Germany
P05.05.
Patient acceptance and compliance of a microbiome-guided colorectal cancer screening: preliminary findings from an observational prospective cohort study
Andrea Severino, Rome, Italy
P05.06.
Operational bias in longitudinal gut microbiota profiling studies: the role of the clinical study coordinator in reducing methodological distortions
Debora Rondinella, Rome, Italy
P05.07.
Gastric Juice Microbiota Signatures Reveal Early Metaplastic Transformation and Support Non-Biopsy Risk Stratification for Gastric Cancer Prevention
Ratha-korn Vilaichone, Pathumthani, Thailand
P05.08.
The effect of complex therapy with the inclusion of the probiotic strain L. paracasei DG on the parameters of the hydrogen-methane breath test in children with gastrointestinal diseases
Aleksandr Shabalov, Saint-Petersburg, Russian Federation
P05.09.
Alcoholic fermentation by Candida albicans
Adriana Barrios, Quetzaltenango, Guatemala
P05.10.
Gut Microbial Taxa and Functions as Markers and Predictors of Gastric Precancerous Lesions: A Longitudinal Cohort Study Using Shotgun Metagenomics
Hyo-Joon Yang, Seoul, Korea, Republic of
P05.11.
Small Intestinal Bacterial Overgrowth in Viral Hepatitis-Related Liver Disease: Association with HCV Activity and Hepatocellular Biochemical Injury
Rashad Hasanov, Baku, Azerbaijan
P05.12.
Small Intestinal Bacterial Overgrowth as a Biochemical Activity Marker in MAFLD and NAS/NASH Spectrum Disease
Rashad Hasanov, Baku, Azerbaijan
P05.13.
Paromomycin is an effective treatment for Enterobacteriaceae overgrowth and related gastrointestinal symptoms: a retrospective analysis
Ernesto Margarita, Rome, Italy
Poster Session 06 - Cancer 1
P06.01.
Ilaprazole versus Esomeprazole for Artificial Ulcer Healing after Gastric Endoscopic Submucosal Dissection: A Single-Center Retrospective Study
Cheol Woong Choi, Yangsan, Korea, Republic of
P06.02.
Pretreatment Sarcopenia Predicts Survival After Endoscopic Submucosal Dissection or Total Gastrectomy for Early Gastric Cancer
Sung Kwan Shin, Seoul, Korea, Republic of
P06.03.
Mechanistic insights into the action of histamine-functionalized PLA nanoparticles loaded with 5-Fluorouracil against gastric cancer cells in vitro.
Weronika Gonciarz, Lodz, Poland
P06.04.
Long-Term Outcomes of Early and Late Metachronous Recurrence After Curative Endoscopic Resection of Early Gastric Cancer
Moon Kyung Joo, Seoul, Korea, Republic of
P06.05.
Impact of Blood Urea Nitrogen Levels on Delayed Bleeding After Gastric Endoscopic Submucosal Dissection
Beom Jin Kim, Seoul, Korea, Republic of
P06.06.
Early-Onset Gastric Cancer Is a Distinct High-Risk Phenotype Marked by Stage-Independent Mortality: : A Large population-based study
Ratha-korn Vilaichone, Pathumthani, Thailand
P06.07.
Serum Pepsinogen and Kyoto Classification Reflect Distinct Dimensions of Gastric Mucosal Changes: A Histology-Based Comparative Study
Ji Yong Ahn, Seoul, Korea, Republic of
P06.08.
Long-term clinical outcomes after endoscopic submucosal dissection for early gastric cancer in elderly patients aged over 75 years: a single-center retrospective study
Samryong Jee, Busan, Korea, Republic of
P06.09.
Optimising Fexuprazan Treatment Duration for Endoscopic Submucosal Dissection–Induced Artificial Gastric Ulcers: A Multicentre, Randomised, Active-Controlled Trial
Da Hyun Jung, Seoul, Korea, Republic of
P06.10.
Identification of Plasma Exosomal miRNA Signatures as Non-invasive Biomarkers for Gastric Dysplasia and Early Gastric Cancer
Gwang Ha Kim,Busan, Korea, Republic of
Poster Session 07 - Helicobacter 5
P07.01.
Prevalence of Helicobacter pylori Infection in dyspeptic children and adults in East and West of Libya: A Multi-Center Study
Ali Almakhrem, Tarhuna, Libya
P07.02.
Comparison of the results 13C-urea breath test and serological diagnostic methods with three different commercial kits for H. pylori infection in the Moscow population
Dmitry Bordin, Moscow, Russian Federation
P07.03.
Effectiveness of reuse of Helicobacter pylori eradication therapies after prior failure: results from the European Registry on H. pylori Management (Hp-EuReg)
Olga P. Nyssen, Madrid, Spain
P07.04.
Evaluation of two molecular assays for the detection of Helicobacter pylori and clarithromycin resistance in stool samples.
Elke Vanlaere, Ghent, Belgium
P07.05.
Diagnosis of HP infection in autoimmune atrophic gastritis.
Tatsiana Haurylenka, Gomel, Belarus
P07.06.
Identification of Helicobacter pylori and its clarithromycin resistance in histologically negative gastric biopsies by quantitative real-time PCR
Gábor Lotz, Budapest, Hungary
P07.07.
Efficacy of postbiotic L.reuteri DSMZ17648 in Helicobacter pylori eradication in children with chronic gastritis
Elena Kornienko, Saint Petersburg, Russian Federation
P07.08.
Empirical second-line treatment in Europe: data from 10,000 cases from the European Registry on Helicobacter pylori Management (Hp-EuReg)
Pablo Parra, Madrid, Spain
P07.09.
T-length variation in the promoter region of nickel-regulated sRNA in Helicobacter pylori isolates from children
Fabrício De Melo, Vitória da Conquista, Brazil
P07.10.
Prevalence of Helicobacter pylori infection among residents of Moscow
Bordin Dmitriy, Moscow, Russian Federation
P07.11
Influence of H.pylori status of frequency of gastroesophageal reflux disease symptoms
Chebotareva Margarita, Moscow, Russian Federation
Poster Session 08 - Helicobacter 6
P08.01.
Current Limitation of PCR-Guided Outcomes of Helicobacter pylori Eradication Therapy
Sujin Kim, Yangsansi, Korea, Republic of
P08.02.
Safety of Helicobacter pylori Eradication Therapies: An analysis of 59,000 Patients from the European Registry on H. pylori Management (Hp-EuReg)
Pablo Parra, Madrid, Spain
P08.03.
Helicobacter Pylori Large Language Models benchmark and fine-tuning using information from the European Registry on H. pylori Management (Hp-EuReg)
Olga P. Nyssen, Madrid, Spain
P08.04.
Effectiveness of first-line empirical Helicobacter pylori treatment outside Europe: results of 15,000 cases from the World-Wide Registry on H. pylori Management (WorldHpReg)
Olga P. Nyssen, Madrid, Spain
P08.05.
Antibiotic-induced biochemical shifts in the preformed Helicobacter pylori biofilm
Paweł Krzyżek, Wroclaw, Poland
P08.06.
Prescription of first-line empirical treatments for Helicobacter pylori infection outside Europe: results from 15,000 cases in the World-Wide Registry on H. pylori Management (WorldHpReg)
Pablo Parra, Madrid, Spain
P08.07.
Epitope-level profiling of CagA antibody response in cancer-associated cohorts
Alex Sirp, Tallinn, Estonia
P08.08.
Investigating predictors of Helicobacter pylori eradication failure in a Latvian population-based screening cohort
Danute Razuka-Ebela, Riga, Latvia
P08.09.
First Canadian data of the World-Wide Registry on Helicobacter pylori Management (WorldHpReg)
Thomas Krahn, Edmonton, Canada
P08.10.
Empirical rescue therapy for Helicobacter pylori infection in Italy: data from the Italian Registry on Helicobacter pylori treatment (Hp-ItaReg)
Rocco Maurizio Zagari, Bologna, Italy
P08.11.
Interleukin (IL)-27 uncouples from immune regulation in pediatric Helicobacter pylori–associated duodenal ulcer
Dulciene De Queiroz, Belo Horizonte, Brazil
P08.12.
Effectiveness and safety of single-capsule bismuth quadruple therapy in 16,000 patients from the European Registry on Helicobacter pylori Management (Hp-EuReg)
Olga P. Nyssen, Madrid, Spain
Poster Session 09 - Helicobacter 7
P09.01.
Optimum second-line regimens for Helicobacter pylori eradication: Results of a systematic review with meta-analysis.
Pablo Parra, Madrid, Spain
P09.02.
Diagnostic Approaches for Helicobacter pylori in Europe: Insights from Over 80,000 Patients in the European Registry on H. pylori Management (Hp-EuReg)
Pablo Parra, Madrid, Spain
P09.03.
Comparative evaluation of selective rapid urease test versus PCR in diagnostic of Helicobacter pylori Infection
Natalia Baryshnikova, St. Petersburg, Russian Federation
P09.04.
Prevalence of vac and jhp genes in H. pylori-associated gastritis and gastric ulcer
Natalia Baryshnikova, St. Petersburg, Russian Federation
P09.05.
Real-world efficacy and safety of adding rebamipide to first-line helicobacter pylori eradication therapy: results from the european registry on H. Pylori management (hp-eureg)
Dmitry Bordin, Moscow, Russian Federation
P09.06.
The metabolic price of cure: Long-term anthropometric, glucose and lipid shifts following quadruple therapies for Helicobacter pylori infection
Elisa Gravito-Soares, Coimbra, Portugal
P09.07.
Targeted Oxford Nanopore sequencing enables culture-free antimicrobial susceptibility testing of Helicobacter pylori for guiding rescue therapies in African clinical settings.
Evariste Tshibangu-Kabamba, Congo, the Democratic Republic of the
P09.08.
Real-World Evidence on Empirical First-Line Treatment of Helicobacter pylori in Mexico: Results from the Latin American Registry on H. pylori management (Hp-LATAMReg)
Ana Delfina Cano Contreras, Veracruz, Mexico
P09.09.
Efficacy and safety of rebamipide in Helicobacter pylori eradication: an umbrella review of meta-analyses
Dmitry Bordin, Moscow, Russian Federation
P09.10.
Impact of molecular methods on the diagnosis and antimicrobial resistance detection of Helicobacter pylori infection in a Greek pediatric population
Beatriz Martinez-Gonzalez, Athens, Greece
P09.11.
MIC drop: The use of efflux pump inhibitor PAβN to reduce minimum inhibitory concentrations in multidrug-resistant Helicobacter pylori
Stephen D. Molloy, Dublin, Ireland
Poster Session 10 - Helicobacter 8
P10.01.
Serological markers as predictors of the severity of gastric mucosal atrophy in autoimmune and H. pylori-associated gastritis
Chebotareva Margarita, Moscow, Russian Federation
P10.02.
Abstract Withdrawn
P10.03.
Prevalence of Helicobacter Pylori and Symptom Burden Among Adults Aged 30-34 in a Western European Country: Preliminary Insights from TOGAS Pilot 1 in Ireland
Orlaith Casey, Dublin, Ireland
P10.04.
Serial Serum Interleukin-8 Trajectories Are Associated With Progression From Helicobacter pylori–Associated Precancerous Lesions to Gastric Cancer: A Prospective Longitudinal Cohort Study
Atteyat Semeya, Benha, Egypt
P10.05.
Effectiveness of Empirical Helicobacter pylori Treatment in Poland: Results from the European Registry on H. pylori Management (Hp-EuReg).
Pablo Parra, Madrid, Spain
P10.06.
Real-World Effectiveness and Safety of Optimised Bismuth-Based Fexuprazan Quadruple Therapy for Helicobacter pylori Eradication in Chile: results from the Latin-American Registry on H. pylori Management (Hp-LATAMReg).
Arnoldo Riquelme, Santiago, Chile
P10.07.
Gut microbiome perturbations and recovery after Helicobacter pylori eradication therapy
Katja Tepeš, Ljubljana, Slovenia
P10.08.
Sibling sRNAs: the missing link between acid stress and CagA-mediated virulence in Helicobacter pylori
Bivash Sinha, Durgapur, India
P10.09.
Molecular sequencing detects metabolically active Helicobacter pylori signal in patients with negative diagnostic clinical tests
Riccardo Vasapolli, Munich, Germany
P10.10.
Unveiling the prevalence of Helicobacter pylori CagA and VacA virulence markers in Moroccan children and adolescents
Hasna Boura, Casablanca, Morocco
P10.11.
The association between Helicobacter pylori IgG sero-prevalence and diabetes mellitus
Khitam Muhsen, Tel Aviv, Israel
P10.12.
The association of Helicobacter pylori infection and inflammation with cognitive development in preadolescents
Khitam Muhsen, Tel Aviv, Israel
Poster Session 11 - Microbiota 2
P11.01.
Healing the Second Brain: The Role of Microbial Modulation and Barrier Repair in Depression Therapy
Alexandra Oros, Cluj-Napoca, Romania
P11.02.
Gastrointestinal Symptoms, Dietary Patterns, and Microbiota Alterations in Children and Young Adults with Autism Spectrum Disorder: ARetrospective Observational Study from a Gastroenterology Outpatient Clinic
Enrico Capuano, Rome, Italy
P11.03.
Circulating microbial DNA in healthy individuals: biological signal or contamination?
Ceu Figueiredo, Porto, Portugal
P11.04.
Gut microbiota changes in Non-Coeliac Gluten/Wheat Sensitivity during Gluten-Free Diet
Federica Marchetti, Ferrara, Italy
P11.05.
A targeted qPCR approach to profile microbial enzymes driving oncometabolite synthesis in gastric cancer
Ceu Figueiredo, Porto, Portugal
P11.06.
Autoprobiotic supplements attenuate obesity and improve gut microbiota, carbohydrate, and lipid metabolism in metabolic syndrome
Natalia Baryshnikova, St. Petersburg, Russian Federation
P11.07.
Long-term gut microbiota changes determined by quadruple therapy regimens in patients with Helicobacter pylori infection in a South-European country: a 16S rRNA gene sequencing and high-throughput sequencing study
Elisa Gravito-Soares, Coimbra, Portugal
P11.08.
Pyridostigmine for functional constipation and constipation-predominant irritable bowel syndrome: a 5-years real world experience
William Fusco, Rome, Italy
P11.09.
Small Intestinal Bacterial and Methanogen Overgrowth in Metabolic and Viral Liver Diseases: A Pooled Comparative Cohort
Rashad Hasanov, Baku, Azerbaijan
P11.10.
Biochemical Characteristics of SIBO-Positive Patients With Chronic Liver Disease: A Pooled Analysis of Metabolic and Viral Etiologies
Rashad Hasanov, Baku, Azerbaijan
P11.11.
Impact of post-processing strategies on metatranscriptomic functional profiles from human tissues with low microbial biomass
Ceu Figueiredo, Porto, Portugal
P11.12.
Lactobacillus rhamnosus K/Ar-08 modulates gut immune homeostasis in experimental autoimmune encephalomyelitis
Natalia Baryshnikova, St. Petersburg, Russian Federation
P11.13.
Influence of probiotics on inbred mice with violation of energy metabolism and gut microbiota
Natalia Baryshnikova, St. Petersburg, Russian Federation
P11.14.
Impact of antibiotic exposure on clinical outcomes and gut microbiome dynamics in patients receiving immune checkpoint inhibitors: preliminary results from the image study
Margherita Ferrari, Rome, Italy
Poster Session 12 - Cancer 2
P12.01.
A rare case of MiNEN in stomach diagnosed after endoscopic resection
Tae Ho Kim
The Catholic University of Korea, Seoul, Korea, Republic of
P12.02.
Proteomic Analysis of Extracellular Vesicles Reveals Vitronectin and Laminin Subunit Alpha-3 as Candidate Biomarkers for Gastric Cancer
Dong Chan Joo, Busan, Korea, Republic of
P12.03.
Multi-omics profiling of OLGIM-staged gastric tissue identifies P1-HNF4a as a stage-associated regulatory isoform
Yun Suk Na, Seoul, Korea, Republic of
P12.04.
Mucosal incision deep biopsy for subepithelial tumors: a useful and safe diagnostic technique
Jeong Seop Moon, Seoul, Korea, Republic of
P12.05.
Microbiome modulation promotes interferon-driven anti-tumor immunity in colorectal cancer
Ceu Figueiredo, Porto, Portugal
P12.06.
Assessment of changes in the pattern of immune cell infiltrate subpopulation in syngeneic MC38 colorectal cancer during course administration of glutamyl-tryptophan: an experimental study
Natalia Baryshnikova, St. Petersburg, Russian Federation
P12.07.
Aberrant p53 expression in gastric intestinal metaplasia mirrors that of adjacent neoplastic lesions: a cross-sectional field cancerization analysis
Emin Mammadov, Baku, Azerbaijan
P12.08.
EUGastScreen: a European implementation study on simultaneous screening for gastric and colorectal cancers
Kateryna Priadko, Riga, Latvia
P12.09.
USF1-202 G/A Polymorphism and Circulating USF1/USF2 Levels as Biomarkers of Gastric Cancer Susceptibility
Ghizlane Bounder, Casablanca, Morocco